Flare Therapeutics and Roche Forge Strategic Partnership to Discover Precision Oncology Therapies Targeting Transcription Factors

FDA Approves Autolus’s CAR-T Therapy Aucatzyl for Relapsed or Refractory B-ALL in Adults

Biosimilars: Expanding Access to Precision Medicine through Affordable Biologic Therapies

IDEAYA Biosciences Secures Exclusive Worldwide License for Biocytogen’s BsADC Program IDE034 for Solid Tumor Treatment

Seer and Thermo Fisher Scientific Announce Strategic Collaboration to Advance Proteomics with Integrated Platform Solution

SystImmune Secures FDA Clearance for IND Application of Novel ADC Therapy BL-M17D1 for Advanced Solid Tumors

Medicare Expands Coverage for Adaptive Biotechnologies' clonoSEQ® MRD Test to Include Mantle Cell Lymphoma

Illumina and PHASE Partner to Advance Oncology Testing in the Greater Bay Area, Supporting the "Healthy China" Initiative

MGI Partners with Human Cell Atlas to Advance Global Human Cell Mapping

NHS Wales and Illumina Expand Partnership to Advance Genomic Cancer Detection and Personalized Medicine

Unlocking Genomic Potential for Rare Cancers: Cancer52 and Genomics England’s Collaborative Approach

Tempus AI Launches Immune Profile Score to Enhance Precision in Immunotherapy for Advanced Cancer Patients

Key Resources and Organizations for Precision Medicine Guidelines

MedGenome Strengthens Leadership Team to Drive North American Expansion in Precision Medicine

NCCN Expands Clinical Practice Guidelines for High-Risk Genetic Cancer Assessment

Home
/
update
/
details

Amrita Hospital in Faridabad Establishes Center of Excellence for CAR T-Cell Therapy

NextEdge Admin

17 Sep 2024

2 min 19 sec

Amrita Hospital, Faridabad, has launched a Centre of Excellence (CoE) for CAR T-cell therapy, a cutting-edge treatment designed to target specific blood cancers like B-cell non-Hodgkin lymphomas and acute lymphoblastic leukemia. The new center aims to provide advanced immunotherapy to patients in the National Capital Region (NCR).

Dr. Sanjeev Singh, Medical Director of Amrita Hospital, emphasized the institution's role as an early adopter of CAR T-cell therapy, noting its pivotal contribution in optimizing these therapies for patients. He highlighted the hospital's evolution from traditional treatments to stem cell transplants and now CAR T-cell therapy, positioning Amrita as a leader in this next-generation cancer treatment.

Dr. Prashant Mehta, Senior Oncologist, stated that the CoE would enhance the accessibility and scalability of CAR T-cell therapies, resulting in more durable remissions for patients in northern India. He also mentioned that the CoE would support Amrita’s clinical and molecular research, expanding CAR T-cell therapy’s application to solid tumors and autoimmune diseases.

Swami Nijamritananda Puri, Administrative Director, underlined the hospital's commitment to providing affordable, innovative healthcare, guided by the vision of accessible treatment for all. He noted the challenges of introducing new therapies but reaffirmed Amrita’s dedication to advancing cancer treatment in India.

Since the CDSCO’s approval of NexCAR19 in October 2023, more than 100 patients have undergone CAR T-cell therapy, with some survivors remaining in remission for over two years, demonstrating the therapy's potential for long-term success.